Schedule of Stock-Based Compensation Expense Classified in Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Stock-based compensation expense	$ 5,203	$ 529	$ 6,639	$ 872
General and Administrative Expense [Member]
Stock-based compensation expense	4,599	343	5,722	586
Research and Development Expense [Member]
Stock-based compensation expense	306	122	417	188
Research and Development Expense [Member] | Lucid Diagnostics Inc [Member]
Stock-based compensation expense	2,580	16	3,385	33
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Stock-based compensation expense	2,505		3,295
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]
Stock-based compensation expense	22	13	34	27
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Stock-based compensation expense	$ 53	$ 3	$ 56	$ 6